Heron Therapeutics Ensures Uninterrupted Supply of Key Medications
Heron Therapeutics, Inc. (Nasdaq: HRTX), a prominent biotechnology company, has reassured healthcare providers about the availability of its critical medications: CINVANTI (aprepitant) and SUSTOL (granisetron), alongside its newly introduced APONVIE medication. These products serve vital roles in preventing Chemotherapy Induced Nausea and Vomiting (CINV) and Postoperative Nausea and Vomiting (PONV), especially during the current potential shortage of intravenous fluids triggered by natural disruptions.
Understanding the Impact of Hurricane Helene
The supply chain for intravenous (IV) fluids has faced considerable disruption due to the temporary halting of production at a key manufacturing facility. This situation arose following Hurricane Helene, which impacted a significant supplier located in the U.S. The facility is known to be the source for nearly sixty percent of the nation's IV fluids. Recognizing the urgency of this situation, Heron Therapeutics has stepped up to emphasize the readiness of its alternative therapies that require no additional dilution with IV fluids.
Craig Collard, CEO of Heron, noted, "Considering the challenges brought about by Hurricane Helene and the anticipated supply disruptions, we are in contact with numerous health systems that are preparing to preserve care continuity during these times of potential shortages." He reiterated the company's resolve to ensure timely delivery of products throughout the country.
Features of CINVANTI and SUSTOL
CINVANTI is specifically designed for the management of nausea related to chemotherapy, available in a ready-to-use injectable form that eliminates the need for further dilution. This formulation is an essential resource for patients undergoing highly emetogenic chemotherapy, such as those receiving high-dose cisplatin. Essentially, it targets both immediate and delayed phases of nausea, ensuring patients experience relief.
On the other hand, SUSTOL offers a comprehensive solution for preventing acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy. Utilizing Heron's advanced Biochronomer® technology, this extended-release injectable delivers therapeutic levels of the active ingredient for an extended duration of five days. This innovative approach marks a significant advancement in providing continuous management for oncology patients.
APONVIE: A New Hope for PONV Relief
For patients experiencing nausea post-surgery, APONVIE presents a viable solution. As an NK1 Receptor Antagonist, it is designed for an effective response to prevent PONV in adults. Administered via a swift IV push, APONVIE has demonstrated efficacy comparable to that of oral aprepitant. This innovation not only boosts patient comfort but also aligns with Heron Therapeutics’ dedication to enhancing therapeutic outcomes for doctors and patients alike.
These three formulations—CINVANTI, SUSTOL, and APONVIE—are readily available through major wholesalers and specialty distributors. For further inquiries, individuals can reach out to the company’s information line.
Commitment to Patient Care During Crises
As healthcare systems navigate the potential challenges posed by the fluid shortage, Heron Therapeutics remains dedicated to patient care and seamless access to necessary treatments. The company prioritizes its responsibility to ensure that healthcare providers can continue to deliver critical medications without disruption. The proactive stance taken by Heron reinforces its commitment to clinical excellence amidst unforeseen challenges.
Frequently Asked Questions
What role does CINVANTI play in cancer treatment?
CINVANTI is crucial for preventing nausea and vomiting in patients undergoing highly emetogenic chemotherapy, ensuring they receive necessary care without additional discomfort from side effects.
How does SUSTOL enhance nausea management?
SUSTOL offers an extended-release solution that provides continuous nausea control for patients undergoing chemotherapy, improving their overall treatment experience.
What is the importance of APONVIE?
APONVIE is vital for preventing postoperative nausea and vomiting, allowing for a quicker recovery and reducing patient discomfort after surgery.
How is Heron able to supply its products during a fluid shortage?
Heron’s products are designed to be ready-to-administer without the need for IV dilution, making them readily available alternatives during supply chain disruptions.
Where can healthcare providers find more information about Heron's products?
Healthcare providers can reach out to Heron Therapeutics directly or consult major wholesalers and specialty distributors for product availability and details.
